SARAH PETERS: Open Payments
NPI 1710529961 · BELLEVUE, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,464 in 112 payments from 23 companies in 2025. Trend: 2023 $1,858 · 2024 $2,850 · 2025 $2,464
Food & beverage: $2,464
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 30 | $688 |
| AstraZeneca Pharmaceuticals LP | 13 | $385 |
| Regeneron Healthcare Solutions, Inc. | 10 | $242 |
| Genentech USA, Inc. | 7 | $177 |
| GlaxoSmithKline, LLC. | 14 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $110 |
| LEO Pharma Inc. | 3 | $85 |
| Novartis Pharmaceuticals Corporation | 3 | $63 |
| Optinose US, Inc. | 3 | $62 |
| Hikma Pharmaceuticals USA | 3 | $58 |
Products named: DUPIXENT, AIRSUPRA, Xolair, NUCALA, FASENRA, Xhance, ADBRY, Ryaltris.
Industry payments across NE — which companies pay providers there.
